Joint ENGOT and GOG Foundation requirements for trials with industry partners

TY - JOUR

T1 - Joint ENGOT and GOG Foundation requirements for trials with industry partners

AU - On behalf of The European Network of Gynaecological Oncological Trial Groups (ENGOT) and The GOG Foundation, Inc

AU - Vergote, Ignace

AU - Coleman, Robert L.

AU - Pignata, Sandro

AU - Bookman, Michael A.

AU - Marth, Christian

AU - Herzog, Thomas J.

AU - Gonzalez Martin, Antonio

AU - Copeland, Larry J.

N1 - Funding Information: Competing interests IV reports: consulting in Advisory Boards of Advaxis, Inc; Eisai Inc.; MSD Belgium; Roche NV, Genmab, F.Hoffmann-La Roche Ltd; Pharmamar; Millennium Pharmaceuticals, Clovis Oncology Inc.; AstraZeneca, Tesaro, Oncoinvent, Immunogen Inc., Sotio. He reports contracted research for Oncoinvent and Genmab; sponsored research from Amgen, Roche and Stichting tegen Kanker; Accomodation and travel expenses from Takeda Oncology, Pharma Mar, Genmab, Roche, Astrazeneca and Tesaro. RLC reports grants from NIH, grants from Gateway Foundation, grants from VFoundation, during the conduct of the study; grants and personal fees from AstraZeneca, grants from Merck, personal fees from Tesaro, personal fees from Medivation, grants and personal fees from Clovis, personal fees from Gamamab, grants and personal fees from Genmab, grants and personal fees from Roche/Genentech, grants and personal fees from Janssen, personal fees from Agenus, personal fees from Regeneron, personal fees from OncoQuest, outside the submitted work. MAB reports: Member of the International Protocol Steering Committees, Genentech-Roche, Mateon, AbbVie, Chair Independent Data Monitoring Committee, Immunogen with reimbursement for time and effort. Participant, ad-hoc advisory boards regarding design of clinical trials, AstraZeneca, Tesaro, Clovis, Merck, Pfizer with reimbursement for time and travel. Employed (full-time) as clinician and Director of Gynecologic Oncology Therapeutics, The Permanente Medical Group (San Francisco CA, USA). CM reports honoraria expenses from Roche, Novartis, Amgen, MSD, PharmaMar, AstraZeneca and Tesaro; Consulting in Advisory Boards of Roche, Novartis, Amgen, MSD, AstraZeneca, Pfizer, PharmaMar, Cerulean, Vertex, Tesaro. TJH reports personal fees from AZ, personal fees from Clovis, personal fees from Genentech, personal fees from J &J, personal fees from Tesaro, personal fees from Caris, outside the submitted work. AG-M reports personal fees from AstraZeneca, personal fees from Tesaro, personal fees from Clovis, personal fees from Roche, personal fees from Pharmamar, personal fees from Inmunogen, personal fees from Genmab, personal fees from MSD, personal fees from Pfizer-Merck, outside the submitted work. LJC reports personal fees from GOG Foundation, personal fees and other from Agenus, personal fees and other from Astra Zeneca, personal fees and other from Clovis Oncology, personal fees and other from Immunogen, personal fees and other from Janssen, personal fees and other from Novocure, personal fees and other from Tesaro, personal fees from Johnson and Johnson, grants from Amgen, grants from VentiRx Pharmaceuticals, grants from Plexxikon, grants from Sanofi, grants from Ludwig, grants from StemCentrx, grants from Tracon, grants from Bristol Meyers, grants from Cerulean/New Genetic Link, grants from Genentech, grants from Regeneron, grants from EMD Serono, grants from Merck, grants from Eisai, grants from Pfizer, grants from Advaxis, grants from La Hoffman Roche, grants from Iovance, grants from Leap Therapeutics, grants from Seattle Genetics, grants from Genmab, grants from Abbvie, outside the submitted work. SP has no conflicts to declare.

PY - 2019/9/1

Y1 - 2019/9/1

KW - cervical cancer

KW - ovarian cancer

KW - uterine cancer

UR - http://www.scopus.com/inward/record.url?scp=85069477802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069477802&partnerID=8YFLogxK

U2 - 10.1136/ijgc-2019-000441

DO - 10.1136/ijgc-2019-000441

M3 - Review article

C2 - 31320391

AN - SCOPUS:85069477802

SN - 1048-891X

VL - 29

SP - 1094

EP - 1097

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

IS - 7

ER -